FLUZONE HIGH-DOSE QIV (Sanofi-Aventis Australia Pty Ltd)
Product name
FLUZONE HIGH-DOSE QIV
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 working days (255)
Active ingredients
influenza virus haemagglutinin
Registration type
NCE/NBE
Indication
FLUZONE HIGH-DOSE QIV (suspension for injection) is indicated for active immunisation for the prevention of influenza disease. Fluzone High-Dose Quadrivalent is indicated for use in persons 65 years of age and older.
The use of Fluzone High-Dose Quadrivalent (QIV) should be based on official recommendations.
See Section 5.1 Clinical Trials for information on the effects on influenza associated complications.